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Case Presentation
LS is a 13-year-old boy who presented with a one month history 
of difficulty in falling asleep. He was accompanied by his mother, 
who asked that he be prescribed some form of sleeping pill to solve 
the problem, because she was worried that it was affecting his 
concentration at school.
DT is a 23-year-old gentleman whose sleep duration had 
decreased progressively over the previous three months, from 5 to 
6 hours per night to a maximum of 2 hours per night. This lower 
extreme had now lasted nearly 3 weeks, and he felt that it was 
completely “wrecking” his daytime routine, with what he described 
as “very low levels of consciousness and alertness” throughout the 
day.
What is insomnia?
Insomnia, from the Latin insomnis, meaning ‘sleepless’, is 
dissatisfaction with the quantity, quality or timing of sleep.1 Patients 
may complain of difficulty falling asleep (prolonged ‘sleep latency’), 
difficulty maintaining sleep (early or multiple awakenings), or 
that the sleep is non-restorative and they do not feel refreshed in 
the morning.2 Insomnia is a subjective symptom, not a disease, 
and the patient’s description may be considered as diagnostic in 
itself.3 However, to be considered a disorder, the complaint must 
be accompanied by distress and/or impairment in the patient’s 
daytime functioning.2  Despite its high prevalence and negative 
impact, it often remains unidentified (Table 1).
Management
Most patients do not mention their sleeping difficulties to their 
doctors because they do not consider the insomnia to be a serious 
problem.8,14 It is therefore important for primary care physicians 
to ask about sleep problems where they might be relevant. The 
management is then based on four steps:
1. A detailed sleep history is essential. Ask a bed partner if 
available. Is there a true problem?
2. A medical, family and drug history will help identify possible 
causes so that they may be treated (Table 2).
3. Non-pharmacological treatment.
4. Pharmacological treatment, where necessary.
A sleep history from LS, confirmed by his mother, showed that 
his main problem was prolonged sleep latency, with a possible 
element of DSPS. Further questions ruled out other treatable causes 
of insomnia (Table 2).
DT’s history revealed longstanding erratic hours, but no other 
obvious cause for the current episode. He did not appear to be under 
any form of psychological stress. However there was the pressing 
problem of his current state, since he felt he could not endure 
another day like the past weeks.
Non-pharmacological treatment: 
Cognitive Behavioural Therapy (CBT)8
CBT has 4 main components – stimulus control, sleep restriction, 
sleep hygiene and cognitive therapy. The first two have been shown 
to be the most effective.3,19
Stimulus Control Therapy 20,21
Established in 1972, stimulus control consists of instructions 
aimed at reducing behaviour incompatible with sleep and regulating 
the sleep-wake cycle. It helps the patient associate the bedroom with 
sleep rather than wakefulness,1 and has been found to be especially 
effective for sleep-onset insomnia.22 
Advice given:
• Go to bed only when sleepy.
• Leave the bed if not asleep within 20 minutes.
• Return to bed only when feeling very sleepy.
• Repeat this cycle as often as necessary.
• Use the bed only for sleeping and sex (no TV, working, 
eating, worrying).
• Wake up at the same time every morning.
• Avoid daytime naps (or at least keep them <1 hour).23
Table 1: The Impact of Insomnia
Prevalence
• Affects 10% of the population (up to 40% in some 
studies)1,4-6
• Females affected more than males (after the onset of 
menses)1,5,7
• Affects up to 50% of those over 65 years old.7
• Insomnia remains unidentified in about 2/3 of 
sufferers.8
Burden on society
• Decreased quality of life, safety and productivity.9 
• Increased healthcare use, motor-vehicle accidents.7,9 
• In the elderly – increased risk of falls and subsequent 
nursing home placement.10
• In adolescents – negative effects on performance, 
emotional and physical health, conduct, substance 
abuse.5,6
• Conservative estimate of the annual cost of insomnia in 
the U.S. - $92.5 to $107.5 billion.11
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Sleep Restriction Therapy 15,21
In use since 1987, the aim here is to constrict the time spent in 
bed to the actual time spent asleep. A sleep diary is kept for circa 
two weeks to establish the average sleep duration. The patient is 
then only allowed to stay in bed for that amount of time (but ideally 
not less than 5 hours20). This may initially cause daytime sleepiness, 
but the time window is gradually increased over a number of weeks 
until adequate sleep duration is achieved.
Sleep Hygiene
This involves educating the patient about the effects of lifestyle 
on sleep. Handouts23 help supplement verbal advice and improve 
patient compliance.
Advice given:
• Stick to a regular bedtime and waking time.23
• Avoid caffeine, nicotine and alcohol during the 6 hours 
before bedtime (but a ‘nightcap’ might help).13
• Avoid large meals close to bedtime (but a light snack might 
help).13
• Decrease evening fluid intake (but a warm, milky drink 
might help).7
• Remove any clocks from sight in the bedroom.13
• Ensure that the bedroom temperature is comfortable.
• Exercise
 Exercise regularly, but not during the 3-4 hours before 
bedtime (except for sex).7,13 Exercising may be the most cost-
effective health intervention for insomniacs,1 and has been 
shown to be as effective as drug treatment (benzodiazepines) 
in improving sleep quality and duration.1,24
• Relaxation
 Relaxation techniques before bedtime help reduce muscular 
and mental tension, arousal, and anxiety. They may 
involve meditation, progressive muscle relaxation, a warm 
bath, or simply a ‘winding-down’ routine such as reading. 
Patients may learn techniques from audiotapes, classes, or 
physiotherapists.7 Relaxation is especially helpful in young 
adults.13 
Cognitive Therapy
During cognitive therapy sessions insomniacs are taught to 
correct any wrong assumptions or perceptions they might have 
about sleep (e.g. ‘we all need 8 hours of sleep’), which may be causing 
anxiety and worsening the problem.21,25 
Cognitive therapy also seeks to enhance one’s ability to cope with 
the stresses which contribute to insomnia,17 as well as reassuring 
the elderly about their natural and expected changes in sleeping 
patterns.21
Table 2: Causes of Insomnia
1. Transient Insomnia 7,12
A few days of insomnia in someone 
who normally sleeps well. 
a.  Environmental Factors 
 e.g. noise, temperature extremes, shift work, jet-lag
b. Life events 
 e.g. upcoming surgery, job stress, exams, deadlines, travel
2. Short-term Insomnia 12
>1 week but <6 months of insomnia
a. Prolongation of transient factors listed above
b. Significant losses (bereavement, separation)
c. Major illness in loved ones
d. Parents with babies
e. Pregnancy (hormonal changes, worries, physical 
discomfort) 7
3. Chronic Insomnia
>6 months of insomnia
a. Medical Disorders1,7,13,14
 Chronic pain of any cause (e.g. arthritis, cancer)
 Respiratory impairment of any cause (e.g. congestive heart 
failure)
 Gastrointestinal (e.g. heartburn, constipation)
 Neurological (e.g. Alzheimer’s, movement disorders, 
headache syndromes)
 Hypertension, Urinary symptoms, Pruritus, Tinnitus, 
Perimenopause
b. Drugs
 Diuretics,15 bronchodilators,16 H
2
 antagonists,13 beta-
adrenoceptor-blockers,12 thyroxine,12 chemotherapy,10 
alcohol,12,15, steroids,7 decongestants,16 stimulants (caffeine, 
nicotine, diet pills10) psychotropics,1 anti-depressants,16 
anti-parkinsonians.15 
c. Psychiatric and Psychological Disorders 1,5
 Anxiety, Depression, Mania, Schizophrenia, Dementia, 
Substance abuse
d. Primary Sleep Disorders 12
 Obstructive sleep apnoea (refer to specialist or sleep clinic) 
 Restless Legs Syndrome (RLS or ‘Ekbom’s syndrome’)
 Narcolepsy
 Circadian rhythm disturbances:
i. Shift-work
ii. Delayed sleep phase syndrome (DSPS) 5
 Often seen in younger patients – lifestyle change 
towards a later bedtime which, when coupled with early 
waking times imposed by school or work, results in less 
sleep. Often identified because the patient has difficulty 
waking, and sleeps normal hours on weekends.
iii. Advanced sleep phase syndrome (ASPS) 5,13
 Often seen in elderly patients – lifestyle change 
towards earlier bedtime, sometimes due to fatigue, with 
accompanying very early awakenings. They may find 
it difficult to stay awake to a more socially acceptable 
bedtime. However, the patient is in fact sleeping an 
adequate number of hours, and reassurance is often all 
that is necessary.
e. Primary Insomnia
 Psycho-physiological Insomnia (most cases):  The patient 
responds to a prolonged period of stress with somatised 
tension and agitation, causing physiological arousal. This 
causes the sleep routine to be associated with frustration 
and arousal, and perpetuates the period of insomnia 
beyond the period of stress. In some primary insomniacs 
this may be due to inefficient coping mechanisms 
– patients experience a normal amount of daily, minor 
stresses, but they perceive the impact as greater, and cope 
by seeking to lessen the emotional distress rather than 
solve the problem. 14,17
8 Malta Medical Journal    Volume 19   Issue 02   June 2007
Does it work? Is it enough?
CBT is practical and easily understood, and therefore appealing 
to patients. It also causes minimal side effects.19,26 More importantly, 
there is a constantly growing evidence-base for its effectiveness. 
Numerous recent studies have shown that CBT is effective and 
superior to placebo,20,26 and comparable with or better than 
pharmacological treatment (hypnotics) in the short-term.19,22,24,27 In 
the long-term, CBT has been shown to give lasting improvements 
in sleep quality,3,19,22,24 with better results than hypnotics.24,27 Other 
studies showed CBT to be suitable and effective in children,6 the 
elderly,19,24 and patients with insomnia secondary to chronic pain.25 
Patient preference is also greater than for hypnotics,24 and CBT use 
has been shown to decrease hypnotic use, cost, and utilisation of 
primary healthcare services in the long-term.22
What are its limitations?
CBT, especially the Cognitive Therapy component, is a time 
consuming treatment which may require referral to a trained 
therapist. Typical courses may involve 4-8 weekly sessions of up 
to an hour each, and therefore substantial patient motivation is 
needed.19,22 The use of CBT is also limited due to initial costs (and 
variable insurance reimbursements), lack of trained providers, and 
poor understanding of what it entails.4,24 Patients may also assume 
that hypnotics are more effective.19 
However, if it is possible to set some time aside, GPs can deliver 
a large proportion of the appropriate advice and education,4,22 and 
CBT has been shown to eventually decrease the burden on the GP, 
despite the initial extra effort and time required.29 GPs are also 
ideally placed to offer ongoing advice and encouragement during 
follow-up. 
Pharmacological Treatment
Hypnotics are drugs that induce sleep, and it must therefore 
be noted that they are relieving the symptom, not treating the 
underlying cause.4
Possible indications for pharmacotherapy:
1. Transient/short term insomnias
 Only 1 or 2 doses, and ideally a drug that is quickly 
eliminated from the body, in order to minimize residual 
effects.12,30
2. Primary insomnia
 e.g. If the patient will benefit from the more rapid effects of 
drug therapy, until the longer-lasting benefits of CBT take 
effect. This also helps prevent untreated short-term insomnia 
from becoming chronic.13  
3. Secondary insomnia due to medical or psychiatric 
disorders.30
4. Occasional use in children with night terrors or 
somnambulism.12
Sedating Antihistamines (e.g. Diphenhydramine)
Most over-the-counter hypnotics contain sedating antihistamines, 
which are effective at inducing drowsiness. However, their sedative 
effects diminish after a few days of continuous treatment.12 Their 
half-life is up to 8 hours, resulting in residual sedation the next day, 
besides various other side-effects.10 
40% of insomniacs resort to self-medication with over-the-
counter preparations, alcohol, or both.4,8 Neither has been proven to 
be any better than placebo when weighing risks versus benefits.1
Alcohol
It is no secret that alcohol induces drowsiness, however it causes 
restless sleep and its diuretic effect interferes with sleep during the 
latter part of the night.12 It should also be discouraged because of 
its abuse potential.
Herbal Remedies (usually containing Valerian Root)
Valerian root has sedative effects and has been shown to be 
superior to placebo for improving sleep quality. It is useful for mild, 
short-term insomnia; however its long-term effects and effectiveness 
are as yet unproven. It causes mild but common side effects such as 
headache, nausea and residual sleepiness, and is costly for patients 
since it is not available on government formularies.31,32
Melatonin
Melatonin is a neurohormone which is secreted by the pineal 
gland at night and suppressed by light, and thereby regulates 
circadian rhythms.13 The evening rise precedes sleepiness by 
around 90-120 minutes. Giving melatonin helps decrease sleep 
latency, but has not produced consistent results with other sleep 
variables.33 Although shown to be safe for short-term use,9 it may 
worsen asthma and epilepsy,33 and cannot be recommended since it 
is unknown whether long-term use is safe or whether it suppresses 
endogenous production.3,33
Benzodiazepines (BDZs)
Introduced in the 1960s, BDZs enhance the effect of Gamma-
Aminobutyric acid (GABA), which is the major inhibitory 
neurotransmitter in the central nervous system.4 They therefore 
have hypnotic, anxiolytic, anticonvulsant and muscle-relaxant 
properties.13 They bring about statistically significant improvements 
in sleep variables.13,28
BDZs commonly cause headache, drowsiness, dizziness, 
rebound insomnia (even after just one night of use), residual 
sedation, respiratory depression, anterograde amnesia and memory 
loss.12-14 Users may develop tolerance within 3-14 days of continuous 
use,12 which may lead to abuse.4,14 It is estimated that 10-30% of 
chronic users are physically and/or psychologically dependent, and 
50% of users suffer withdrawals after stopping the drug.4 BDZ use 
also increases the risk of motor-vehicle accidents and falls leading 
to femur fractures.1,10
There is virtually no evidence to support the chronic use of BDZs 
for insomnia, since despite all the adverse effects listed above, long-
term clinical benefits are modest at best.4,12,22,28
In view of the above, the Committee on Safety of Medicines 
12 advises that BDZs should only be used in insomnia when it is 
‘severe, disabling, or subjecting the individual to extreme distress’. 
One should aim for intermittent use, and the lowest effective dose. 
Even then, use should never exceed 3 weeks in duration (preferably 
1 week), and a rapidly-eliminated drug should be used.12
Despite all this evidence of major harm, BZD prescribing 
continues to grow, and patient satisfaction remains high, despite 
adverse effects.15 They remain common in the primary care setting,22 
with over two thirds of users having been started on the drug by 
their family doctor.34 One need only pay a short visit to one of the 
local prescription clinics in the Primary Health Care Department to 
see ample evidence of widespread long-term use, even amongst the 
frail and elderly. It is estimated that chronic users make up around 
2% of the population.34
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Z-Drugs (Zolpidem [Stilnox®], Zopiclone, Zaleplon)
Developed in the 1980s, Z-Drugs differ structurally from BDZs 
but are also GABA-agonists. Although initially championed as 
having lesser side effects, there is lack of compelling evidence to 
distinguish between them and the shorter-acting BDZs with regards 
to effectiveness, adverse effects or potential for dependence.4,10 The 
UK’s National Institute for Clinical Evidence (NICE) therefore 
advises that one simply choose the cheaper drug, and that one 
switches from a BDZ to a Z-Drug only if there is a complaint of 
adverse effects.4
A 15-20 minute discussion about sleep hygiene with LS and his 
mother brought out several possible improvements in his lifestyle 
and sleep routine. A list of changes was drawn up, and he agreed 
to put them into practice over the following weeks. It was also 
explained to the mother why drug treatment was not indicated. 
He did not return for follow-up, but during a non-related visit 
by his mother a few months later she confirmed that the problem 
had resolved.
DT was prescribed a short-acting BDZ for 2 weeks, during 
which he managed to sleep better, and his daytime functioning 
improved. He then stopped the hypnotics, and experienced three 
days of rebound insomnia, which he had been warned about, 
but his sleeping then improved. In the meantime, he had slowly 
started implementing various behavioural modifications. At 
follow-up visits he reported an improved overall sleep duration, 
and ‘improved capacity to handle stress and pressure’, which he 
felt had a direct effect on his sleeping. Over the following year he 
maintained an average of 5 hours of sleep per night, but more 
importantly he now feels that his daytime functioning has returned 
to normal.
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